Related Experiment Video
Updated: Jun 12, 2026

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
Corrigendum to: Nanoparticle-Mediated Transcytosis in Tumor Drug Delivery: Mechanisms, Categories, and Novel
Nakaooh Doaa1, Signa Lon Rolande Detorgma1, Kaiyun Yang2
1Department of Pharmaceutics, China Pharmaceutical University, Nanjing, 210009, PR China.
Abstract:
In the published article [1], text under heading 5 was inadvertently omitted during the final processing of the manuscript. This error has now been corrected, and the references have been updated. This correction does not affect the scientific content, data interpretation, or conclusions of the article. The original article is available online at: https://www.benthamscience.com/article/143767 The publisher apologizes for any inconvenience caused to the authors and readers. Details of the correction is provided below: Corrected: 5. THE DIFFERENCE BETWEEN AMT, RMT, AND CMT AMT, RMT, and CMT represent distinct transcytosis mechanisms: AMT relies on non-specific electrostatic interactions, RMT depends on specific binding to cellsurface receptors, while CMT utilizes carrier cells (e.g., immune cells) to transport drugs or nanoparticles. The key differences between these mechanisms are summarized in Table 2.
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
